What advancements have been made in the storage and transport of factors used in factor XIII (FXIII) deficiency treatment?

Updated: Aug 01, 2019
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print

Advances in the types of available products improve care. Addition of Tween 20 makes a reduction of the generation of soluble and insoluble aggregates of rFXIII possible when rFXIII is subjected to freezing and thawing or agitation. [115] Another advance in the technology relates to solving problems faced during freeze-drying and storing the dry solid. Improvement in storage stability of therapeutic proteins has obvious advantages for both storage and transport. [116]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!